Description: We sought to determine whether short-term neoadjuvant androgen deprivation (STAD) duration influences the optimal time point from which Phoenix fail (time to biochemical failure; TTBF) should be measu... More

Description: The editorial 'PSA testing in asymptomatic men to diagnose prostate cancer remains experimental' by Cox and Sneyd — which appeared in the 5 June 2009 issue of the NZMJ — denigrated the importance of t... More

Description: Background: The relative effects of radiation dose escalation (RDE) and androgen suppression (AS) duration on local prostatic progression (LP) remain unclear. Methods: We addressed this in the TROG 03... More

Description: BACKGROUND: Androgen suppression therapy and radiotherapy are used to treat locally advanced prostate cancer. 3 years of androgen suppression confers a small survival benefit compared with 6 months of... More

Description: Background: Long-term prostate cancer (PCa) survivors are at increased risk for comorbidities and physical deconditioning.Objective: To determine the effectiveness of a year-long randomised controlled... More

Description: Background: Surrogate endpoints for prostate cancer-specific mortality after curative primary treatment are not well established. We sought to assess time to biochemical failure (TTBF) and prostate-sp... More

Description: Purpose: We sought to compare the prognostic value of early prostate-specific antigen (PSA) test-based variables for the 802 eligible patients treated in the Trans-Tasman Radiation Oncology Group 96.0... More

Description: Purpose: We studied prostate-specific antigen (PSA) changes after radiation with or without neoadjuvant androgen deprivation to determine posttreatment PSA scenarios in which false-positive biochemica... More

Description: Background: We sought to determine whether inter-patient variations in pattern of PSA changes after radiation exist and, if so, are they prognostically significant. Methods: In the Trans-Tasman Radiat... More

Description: Background and purpose: Temporal distributions in PSA levels following therapeutic intervention for prostate cancer are known to contain characteristics prognostic of disease progression. An algorithm... More

Description: Background: Androgen deprivation therapy leads to a number of adverse effects including deterioration of the musculoskeletal system and increased risk factors for cardiovascular and metabolic complica... More